RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Telix Pharmaceuticals Stock

Telix Pharmaceuticals Net Income 2025

Telix Pharmaceuticals Net Income

40.39 M AUD

Ticker

TLX.AX

ISIN

AU000000TLX2

WKN

A2H7JK

In 2025, Telix Pharmaceuticals's profit amounted to 40.39 M AUD, a 23.63% increase from the 32.67 M AUD profit recorded in the previous year.

The Telix Pharmaceuticals Net Income history

YEARNET INCOME (M AUD)
2030e606.74
2029e409.27
2028e294.25
2027e132.64
2026e61.9
2025e40.39
202432.67
20233.41
2022-68.11
2021-80.51
2020-44.89
2019-27.87
2018-13.83
2017-6.38

Telix Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Telix Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Telix Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Telix Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Telix Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Telix Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Telix Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Telix Pharmaceuticals’s growth potential.

Telix Pharmaceuticals Revenue, EBIT and net profit per share

DateTelix Pharmaceuticals RevenueTelix Pharmaceuticals EBITTelix Pharmaceuticals Net Income
2030e2.84 B undefined0 undefined606.74 M undefined
2029e2.43 B undefined632.93 M undefined409.27 M undefined
2028e2.14 B undefined483.68 M undefined294.25 M undefined
2027e1.66 B undefined205.19 M undefined132.64 M undefined
2026e1.32 B undefined122.31 M undefined61.9 M undefined
2025e1.09 B undefined62.72 M undefined40.39 M undefined
2024512.53 M undefined52.29 M undefined32.67 M undefined
2023328.87 M undefined11.53 M undefined3.41 M undefined
2022104.77 M undefined-59.43 M undefined-68.11 M undefined
20217.6 M undefined-76.95 M undefined-80.51 M undefined
20205.21 M undefined-35.6 M undefined-44.89 M undefined
20193.49 M undefined-28.36 M undefined-27.87 M undefined
2018195,100 undefined-17.51 M undefined-13.83 M undefined
20170 undefined-6.16 M undefined-6.38 M undefined

Telix Pharmaceuticals stock margins

The Telix Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Telix Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Telix Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Telix Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Telix Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Telix Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Telix Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Telix Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Telix Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Telix Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Telix Pharmaceuticals Margin History

Telix Pharmaceuticals Gross marginTelix Pharmaceuticals Profit marginTelix Pharmaceuticals EBIT marginTelix Pharmaceuticals Profit margin
2030e61.79 %0 %21.37 %
2029e61.79 %26.01 %16.82 %
2028e61.79 %22.57 %13.73 %
2027e61.79 %12.33 %7.97 %
2026e61.79 %9.27 %4.69 %
2025e61.79 %5.74 %3.7 %
202461.79 %10.2 %6.37 %
202362.56 %3.5 %1.04 %
202259.29 %-56.72 %-65.01 %
202166.46 %-1,012.97 %-1,059.9 %
202061.17 %-682.89 %-861.06 %
201927.03 %-813.74 %-799.63 %
201861.79 %-8,972.32 %-7,088.57 %
201761.79 %0 %0 %

Telix Pharmaceuticals Aktienanalyse

What does Telix Pharmaceuticals do?

Telix Pharmaceuticals Ltd. is a leading biopharmaceutical company specializing in the development of diagnostic and therapeutic solutions that work at the molecular level. The company's activities span across Europe, North America, and the Asia-Pacific region. Telix was formed through the merger of two Australian companies - Advanced Nuclear Medicine Ingredients (ANMI) and Radiopharmaceuticals Pty Ltd. The company's business model is based on translational medicine and it works closely with academic research groups and international partners to develop products and technologies aligned with the latest medical research and scientific knowledge. Telix has two main business divisions: Imaging and Therapy. The Imaging division focuses on the development of diagnostic radiopharmaceuticals for cancer and inflammation imaging, while the Therapy division concentrates on the development of radiopharmaceuticals for the treatment of cancer and other chronic diseases. The company offers a wide portfolio of products and solutions tailored to diseases of the nervous and immune systems, as well as to cancer diagnosis and treatment. These include the Prostate-Specific Membrane Antigen (PSMA)-targeting technology, which has the potential to significantly improve the early diagnosis and progression of prostate cancer, radiopharmaceuticals for bone imaging to enhance the diagnosis of bone metastases and other bone diseases, and radiopharmaceuticals for cancer therapy that show promising results in precision tumor treatment. Telix Pharmaceuticals aims to improve the diagnosis, treatment, and quality of life for patients with chronic diseases through its innovative products, strong network of partners, and commitment to entrepreneurial excellence. Telix Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Telix Pharmaceuticals's Profit Margins

The profit margins of Telix Pharmaceuticals represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Telix Pharmaceuticals's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Telix Pharmaceuticals's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Telix Pharmaceuticals's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Telix Pharmaceuticals’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Telix Pharmaceuticals stock

How much profit has Telix Pharmaceuticals made this year?

Telix Pharmaceuticals has made 40.39 M AUD this year.

How has the profit developed compared to last year?

The profit has increased by 23.63% compared to last year increased

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Telix Pharmaceuticals publish its earnings?

Telix Pharmaceuticals publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Telix Pharmaceuticals?

The profits of Telix Pharmaceuticals are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Telix Pharmaceuticals?

You can learn more about the earnings of Telix Pharmaceuticals by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Telix Pharmaceuticals pay?

Over the past 12 months, Telix Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Telix Pharmaceuticals is expected to pay a dividend of 0 AUD.

What is the dividend yield of Telix Pharmaceuticals?

The current dividend yield of Telix Pharmaceuticals is .

When does Telix Pharmaceuticals pay dividends?

Telix Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Telix Pharmaceuticals?

Telix Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Telix Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Telix Pharmaceuticals located?

Telix Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Telix Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Telix Pharmaceuticals from 10/1/2025 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 10/1/2025.

When did Telix Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/1/2025.

What was the dividend of Telix Pharmaceuticals in the year 2024?

In the year 2024, Telix Pharmaceuticals distributed 0 AUD as dividends.

In which currency does Telix Pharmaceuticals pay out the dividend?

The dividends of Telix Pharmaceuticals are distributed in AUD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Telix Pharmaceuticals

Our stock analysis for Telix Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Telix Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.